Mounjaro in Belgien, online

Wie wirkt Mounjaro?

Copies two gut hormones. Tirzepatide activates the receptors for two natural gut hormones, GIP and GLP-1, which the body releases after eating. The EU product information describes it as a long acting GIP and GLP-1 receptor agonist that binds both receptors with high affinity.

Turns down appetite signals. Both of those receptors also sit in the brain areas that regulate appetite. Clinical studies cited in the product information report that tirzepatide reduces energy intake and appetite by increasing feelings of satiety and fullness, and by decreasing feelings of hunger.

Slows the stomach, steadies glucose. Tirzepatide delays gastric emptying, so food leaves the stomach more slowly after a meal. It also increases insulin release in a glucose dependent way and lowers glucagon. The weight change comes mainly from eating less, and is mostly a loss of fat mass.

Anwendung von Mounjaro

Pick one day each week. Tirzepatide is injected once a week, at any time of day, with or without food. Pick a day that is easy to remember. You can change the day later as long as three days separate two doses.

Store pens in the fridge. Unused pens are kept in a refrigerator between 2 and 8 degrees Celsius, in the original carton so light cannot reach them, and must never be frozen. A pen that has been frozen must not be used.

Check the pen before use. Look at the liquid before you inject. It should be clear and free of particles or discolouration. Discard the pen if you can see anything floating in it, if it looks discoloured, or if it is out of date.

Inject into tummy, thigh or arm. Tirzepatide goes under the skin of the abdomen, the thigh or the upper arm. The back of the upper arm needs another person to do the injection. Read the instructions for use packed with the pen first.

Rotate the spot every week. Injection sites should be rotated with each dose, so the same patch of skin is not used week after week. If you also inject insulin, use a different site for each of the two medicines.

Missed dose: the four day rule. If you remember within four days, inject then and return to your usual schedule. If more than four days have passed, skip that dose and take the next one on the normal day. Never inject two doses to catch up.

Know how long a pen lasts. Single-dose pens and vials may be kept out of the refrigerator for up to 21 cumulative days below 30 degrees Celsius, then discarded. A multi-dose KwikPen holds four weekly doses and is thrown away 30 days after first use.

Keep the diet and activity going. Tirzepatide is licensed as an addition to a reduced-calorie diet and increased physical activity, not as a replacement for them. Every trial result quoted on this page comes from people doing both alongside the weekly injection.

Häufige Nebenwirkungen

Stop and get urgent medical help if (seek medical help immediately): Severe, persistent pain in the stomach area, with or without nausea and vomiting, which can signal pancreatitis, Breathing problems, or rapid swelling of the lips, tongue or throat, Difficulty swallowing together with a fast heartbeat, which can signal a severe allergic reaction, Vomiting or diarrhoea so severe or so lasting that you cannot keep fluids down, because dehydration can damage the kidneys, Pain in the upper right of the tummy with fever, or yellowing of the skin or eyes, Shakiness, sweating and confusion, if you also take insulin or a sulfonylurea for diabetes

Very common (very common (≥1/10)): Feeling sick (nausea), most often while the dose is being increased, Diarrhoea, usually mild or moderate, and easing over time

Common (common (≥1/100 to <1/10)): Vomiting, Constipation, Pain in the stomach area (abdomen), Indigestion, bloating, burping, wind or acid reflux, Tiredness, weakness or generally feeling unwell, Injection site reactions, most often redness and itching, Dizziness, or low blood pressure, A faster heart rate, Hair loss, Hypersensitivity reactions such as rash and dermatitis, Raised lipase or amylase on blood tests

Uncommon (uncommon (≥1/1,000 to <1/100)): Gallstones, or inflammation of the gallbladder (cholecystitis), Acute pancreatitis, which is inflammation of the pancreas, Pain at the injection site, Raised blood calcitonin, seen only on a blood test, Delayed stomach emptying, listed as uncommon in UK labelling

Rare (rare (≥1/10,000 to <1/1,000)): Anaphylactic reaction, a sudden and severe whole-body allergic reaction, Angioedema, deep swelling under the skin, often of the face or throat

Nehmen Sie Mounjaro nicht ein, wenn

• You have ever had an allergic reaction to tirzepatide or to any other ingredient in the pen.
• You are pregnant or planning a pregnancy. Tirzepatide is not recommended in pregnancy or in women of childbearing potential not using contraception.
• You are breastfeeding. A risk to the infant cannot be excluded, so the prescriber weighs continuing feeding against continuing treatment.
• You have had pancreatitis. Tirzepatide has not been studied in these patients and should be used with caution.
• You have severe gastrointestinal disease, including severe gastroparesis. Tirzepatide has not been studied in this group.
• You have proliferative diabetic retinopathy, diabetic macular oedema, or retinopathy needing acute treatment. Caution and monitoring apply.
• You are under 18 years old. Safety and efficacy for weight management have not been established below that age.
• You have severe kidney impairment, end stage renal disease, or severe liver impairment. Experience is limited, so caution applies.
• You are booked for general anaesthesia or deep sedation. Tell the team you take tirzepatide, because pulmonary aspiration has been reported.

Arzneimittel und Substanzen mit Wechselwirkungen

• Oral medicines in general: Tirzepatide delays gastric emptying, so tablets can be absorbed more slowly, especially at the start. Most oral medicines need no dose change. The prescriber reviews your full list.
• Warfarin, digoxin and other narrow therapeutic index drugs: Absorption can shift when tirzepatide is started or the dose is increased. The prescriber monitors you more closely at initiation and after each dose increase.
• Sulfonylureas (for example gliclazide): Combined use raises the risk of low blood sugar in people with type 2 diabetes. The prescriber may reduce the sulfonylurea dose and ask for blood glucose self-monitoring.
• Insulin: Combined use raises hypoglycaemia risk; clinically significant lows occurred in 14 to 19 percent. The prescriber reduces insulin stepwise and arranges blood glucose self-monitoring.
• Combined oral contraceptives: A single 5 mg dose reduced ethinylestradiol peak level by 59 percent and delayed it four hours. EU labelling requires no dose change. UK labelling advises adding a barrier method for four weeks.
• Paracetamol: A single 5 mg dose halved the paracetamol peak level and delayed it by one hour. No dose adjustment needed. Overall exposure was unchanged after four consecutive weekly doses.
• Oral medicines where rapid onset matters: Delayed gastric emptying can postpone the effect of a tablet you need to work quickly. The prescriber considers timing, a non-oral route, or an alternative medicine.

Quellen

1. Mounjaro (tirzepatide): European public assessment report, medicine overview European Medicines Agency, 2022
2. Mounjaro: Annex I Summary of Product Characteristics European Commission Union Register of Medicinal Products, 2024
3. Mounjaro KwikPen 5 mg solution for injection in pre-filled pen: Summary of Product Characteristics electronic medicines compendium (emc), 2026
4. Mounjaro KwikPen 15 mg solution for injection in pre-filled pen: Summary of Product Characteristics electronic medicines compendium (emc), 2026
5. Mounjaro KwikPen 5 mg: Patient Information Leaflet electronic medicines compendium (emc), 2026
6. Tirzepatide (Mounjaro): NHS medicines A to Z NHS, 2026
7. SURMOUNT-1: Tirzepatide once weekly for the treatment of obesity New England Journal of Medicine, 2022
8. SURMOUNT-2: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes The Lancet, 2023
9. SURMOUNT-4: Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity JAMA, 2024
10. STEP 1: Once-weekly semaglutide in adults with overweight or obesity New England Journal of Medicine, 2021
11. SCALE Obesity and Prediabetes: a randomized, controlled trial of 3.0 mg of liraglutide in weight management New England Journal of Medicine, 2015
12. XENDOS: XENical in the prevention of Diabetes in Obese Subjects, a 4-year randomised study Diabetes Care, 2004
13. Wegovy 2.4 mg FlexTouch solution for injection: Summary of Product Characteristics electronic medicines compendium (emc), 2026
14. Saxenda 6 mg/mL solution for injection: Summary of Product Characteristics electronic medicines compendium (emc), 2026
15. Xenical 120 mg hard capsules: Summary of Product Characteristics electronic medicines compendium (emc), 2026
16. CIMA: Mounjaro presentations, marketing and prescription status in Spain AEMPS (Spanish Agency of Medicines and Medical Devices), 2026
17. MOUNJARO (tirzépatide), obésité: avis de la Commission de la Transparence Haute Autorité de Santé, 2025
18. Obésité: prise en charge de WEGOVY et MOUNJARO à partir du 15 juin 2026, sous conditions VIDAL, reporting the arrêté published in the Journal officiel, 2026
19. Tirzepatide (Mounjaro): monograph and reimbursement status in Belgium BCFI / CBIP, Belgian Centre for Pharmacotherapeutic Information, 2024
20. Find a Medicine: authorised medicines database Health Products Regulatory Authority (Ireland), 2026
21. Medicijnkosten.nl: medicine reimbursement database Zorginstituut Nederland, 2026
22. INFOMED: base de dados de medicamentos de uso humano INFARMED (Portugal), 2026

Auch verfügbar in

• Sevilla
• Málaga
• Córdoba
• Granada
• Jerez de la Frontera
• Almería
• Huelva
• Cádiz
• Jaén
• Marbella
• Zaragoza
• Huesca
• Teruel
• Oviedo
• Gijón
• Avilés
• Palma de Mallorca
• Ibiza
• Mahón
• Las Palmas de Gran Canaria
• Santa Cruz de Tenerife
• San Cristóbal de La Laguna
• Telde
• Arona
• Santander
• Toledo
• Valladolid
• Barcelona
• Valencia
• Alicante
• Mérida
• Vigo
• Santiago de Compostela
• Logroño
• Madrid
• Murcia
• Pamplona
• Bilbao
• Vitoria-Gasteiz
• San Sebastián
• Berlin
• Hamburg
• München
• Köln
• Frankfurt
• Stuttgart
• Düsseldorf
• Leipzig
• Dortmund
• Essen
• Paris
• Marseille
• Lyon
• Toulouse
• Nizza
• Nantes
• Montpellier
• Straßburg
• Bordeaux
• Lille
• Rom
• Mailand
• Neapel
• Turin
• Palermo
• Genua
• Bologna
• Florenz
• Bari
• Catania
• Warschau
• Krakau
• Łódź
• Breslau
• Poznań
• Danzig
• Szczecin
• Bydgoszcz
• Amsterdam
• Rotterdam
• Den Haag
• Utrecht
• Eindhoven
• Groningen
• Tilburg
• Almere
• Brüssel
• Antwerpen
• Gent
• Charleroi
• Lüttich
• Brügge
• Namur
• Lissabon
• Porto
• Vila Nova de Gaia
• Amadora
• Braga
• Coimbra
• Bukarest
• Cluj-Napoca
• Iași
• Timișoara
• Constanța
• Craiova
• Athen
• Thessaloniki
• Patras
• Piräus
• Prag
• Brno
• Ostrava
• Pilsen
• Budapest
• Debrecen
• Szeged
• Miskolc
• Wien
• Graz
• Linz
• Salzburg
• Stockholm
• Göteborg
• Malmö
• Uppsala
• Västerås
• Helsinki
• Espoo
• Tampere
• Vantaa
• Kopenhagen
• Aarhus
• Odense
• Aalborg
• Dublin
• Cork
• Limerick
• Galway
• Sofia
• Plovdiv
• Varna
• Burgas
• Bratislava
• Košice
• Prešov
• Žilina
• Zagreb
• Split
• Rijeka
• Osijek
• Vilnius
• Kaunas
• Klaipėda
• Šiauliai
• Panevėžys
• Ljubljana
• Maribor
• Celje
• Riga
• Daugavpils
• Liepāja
• Jelgava
• Tallinn
• Tartu
• Narva
• Nicosia
• Limassol
• Larnaca
• Paphos
• Luxemburg
• Esch-sur-Alzette
• Valletta
• Birkirkara
• Qormi
• Mosta
• Spanien
• Frankreich
• Deutschland
• Italien
• Portugal
• Niederlande
• Irland
• Polen
• Tschechien
• Slowakei
• Ungarn
• Rumänien
• Bulgarien
• Griechenland
• Zypern
• Kroatien
• Slowenien
• Österreich
• Dänemark
• Schweden
• Finnland
• Estland
• Lettland
• Litauen
• Luxemburg
• Malta